IBT portfolio company Apellis acquired by Biogen

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) announced that its portfolio company, Apellis Pharmaceuticals, has agreed to be acquired by Biogen for approximately $5.6 billion, with Apellis shareholders to receive $41 per share in cash, representing a 140% premium. Apellis, which has two approved drugs, Empaveli and Syfovre, represented 2.5% of IBT's Net Asset Value as of March 30th. IBT's portfolio managers highlighted this as the third acquisition from their portfolio in March, underscoring the ongoing M&A activity in the biotech sector and IBT's strategy to capitalize on such opportunities. The updated valuation of IBT's holding in Apellis will be reflected in the company's NAV as of March 31st.

Disclaimer*

UK 100

Latest directors dealings